NeoGenomics, Inc. (NASDAQ:NEO) CAO Kathryn B. Mckenzie sold 8,000 shares of the business’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $26.37, for a total transaction of $210,960.00. Following the sale, the chief accounting officer now directly owns 10,273 shares of the company’s stock, valued at $270,899.01. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Shares of NASDAQ NEO opened at $26.69 on Friday. NeoGenomics, Inc. has a 52-week low of $11.05 and a 52-week high of $27.23. The firm has a fifty day moving average of $23.98 and a 200-day moving average of $23.04. The stock has a market capitalization of $2.74 billion, a PE ratio of 205.27 and a beta of 1.04. The company has a quick ratio of 4.05, a current ratio of 4.24 and a debt-to-equity ratio of 0.24.

NeoGenomics (NASDAQ:NEO) last announced its quarterly earnings data on Tuesday, October 29th. The medical research company reported $0.07 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.06 by $0.01. The company had revenue of $104.70 million during the quarter, compared to analysts’ expectations of $99.38 million. NeoGenomics had a net margin of 0.55% and a return on equity of 4.60%. The business’s quarterly revenue was up 51.5% compared to the same quarter last year. During the same period in the previous year, the company earned $0.05 EPS. Equities research analysts expect that NeoGenomics, Inc. will post 0.19 EPS for the current fiscal year.

Several brokerages have recently issued reports on NEO. Needham & Company LLC boosted their price objective on shares of NeoGenomics from $27.00 to $29.00 and gave the company a “buy” rating in a research note on Wednesday, October 30th. William Blair reissued an “outperform” rating on shares of NeoGenomics in a research note on Tuesday, October 29th. BidaskClub raised shares of NeoGenomics from a “hold” rating to a “buy” rating in a research note on Friday. ValuEngine cut shares of NeoGenomics from a “buy” rating to a “hold” rating in a research note on Tuesday, December 3rd. Finally, Zacks Investment Research raised shares of NeoGenomics from a “sell” rating to a “hold” rating in a research note on Tuesday, November 5th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $25.00.

Large investors have recently bought and sold shares of the stock. Captrust Financial Advisors acquired a new position in shares of NeoGenomics during the 2nd quarter valued at $66,000. Nisa Investment Advisors LLC lifted its holdings in shares of NeoGenomics by 867.5% during the 3rd quarter. Nisa Investment Advisors LLC now owns 3,870 shares of the medical research company’s stock valued at $74,000 after acquiring an additional 3,470 shares in the last quarter. Benjamin F. Edwards & Company Inc. lifted its holdings in shares of NeoGenomics by 75.0% during the 3rd quarter. Benjamin F. Edwards & Company Inc. now owns 4,550 shares of the medical research company’s stock valued at $87,000 after acquiring an additional 1,950 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of NeoGenomics by 14.7% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,778 shares of the medical research company’s stock valued at $110,000 after acquiring an additional 739 shares in the last quarter. Finally, NumerixS Investment Technologies Inc acquired a new position in shares of NeoGenomics during the 2nd quarter valued at $169,000. Institutional investors and hedge funds own 83.49% of the company’s stock.

About NeoGenomics

NeoGenomics, Inc, together with its subsidiaries, operates a network of cancer-focused genetic testing laboratories in the United States; and laboratories in Switzerland and Singapore. It operates in two segments, Clinical Services and Pharma Services. The company's laboratories provide genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, pharmaceutical firms, academic centers, and other clinical laboratories.

Featured Story: What are economic reports?

Insider Buying and Selling by Quarter for NeoGenomics (NASDAQ:NEO)

Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.